MCID: TRP003
MIFTS: 24

Triple-Receptor Negative Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Triple-Receptor Negative Breast Cancer

MalaCards integrated aliases for Triple-Receptor Negative Breast Cancer:

Name: Triple-Receptor Negative Breast Cancer 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0060081

Summaries for Triple-Receptor Negative Breast Cancer

Disease Ontology : 12 A breast cancer that is characterized by the absence of estrogen, progresterone and Her2 receptors.

MalaCards based summary : Triple-Receptor Negative Breast Cancer is related to breast cancer and peritoneum cancer. An important gene associated with Triple-Receptor Negative Breast Cancer is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are Phospholipase D signaling pathway and Lysosphingolipid and LPA receptors. The drugs Pembrolizumab and Antineoplastic Agents, Immunological have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and brain.

Related Diseases for Triple-Receptor Negative Breast Cancer

Graphical network of the top 20 diseases related to Triple-Receptor Negative Breast Cancer:



Diseases related to Triple-Receptor Negative Breast Cancer

Symptoms & Phenotypes for Triple-Receptor Negative Breast Cancer

Drugs & Therapeutics for Triple-Receptor Negative Breast Cancer

Drugs for Triple-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pembrolizumab Approved Phase 3 1374853-91-4
2 Antineoplastic Agents, Immunological Phase 3
3
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
4
Epirubicin Approved Phase 2 56420-45-2 41867
5
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
6
Fluorouracil Approved Phase 2 51-21-8 3385
7
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
8
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
9
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
10
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
11
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
12
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
13 Alkylating Agents Phase 2
14 Anti-Infective Agents Phase 2
15 Topoisomerase Inhibitors Phase 2
16 Antibiotics, Antitubercular Phase 2
17 Anti-Bacterial Agents Phase 2
18 Antifungal Agents Phase 2
19 Antirheumatic Agents Phase 2
20 Immunosuppressive Agents Phase 2
21 Antimitotic Agents Phase 2
22 Albumin-Bound Paclitaxel Phase 2
23 Antibodies, Monoclonal Phase 2
24 Antibodies Phase 2
25 Immunoglobulins Phase 2
26 Antimetabolites Phase 2
27 Immunologic Factors Phase 2
28 Mitogens Phase 2
29 Protein Kinase Inhibitors Phase 2
30 taxane Phase 2
31
Erlotinib Hydrochloride Phase 2 183319-69-9 176871

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy Recruiting NCT02954874 Phase 3
2 Open Label Randomized Clinical Trial of Standard Neoadjuvant Chemotherapy (Paclitaxel Followed by FEC) Versus the Combination of Paclitaxel and RAD001 Followed by FEC in Women With Triple Receptor-Negative Breast Cancer (CRAD001C24101) Unknown status NCT00499603 Phase 2 Paclitaxel;5-Fluorouracil;Epirubicin;Cyclophosphamide;RAD001
3 An Open-label, Randomized, Controlled Phase-II Trial Evaluating the Efficacy and Safety of EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients Completed NCT00448305 Phase 2 EndoTAG-1 + paclitaxel;EndoTAG-1;Paclitaxel
4 Recombinant Anti-EGFR Monoclonal Antibody(SCT200) in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer : a Phase Ⅱ, Open-label, Single-arm, Multicenter Study Recruiting NCT03692689 Phase 2
5 Randomized, Phase II Trial to Evaluate the Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy Compared to Capecitabine Monotherapy for TNBC With Residual Invasive Cancer After Neoadjuvant Chemotherapy. Not yet recruiting NCT03756298 Phase 2 Atezolizumab;Capecitabine
6 PHASE 2 STUDY OF SINGLE-AGENT PF-03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS Terminated NCT02299635 Phase 2 PF-03084014;PF-03084014;PF-03084014
7 Study of Erlotinib, Small Molecule Targeting Epidermal Growth Factor Receptor (EGFR) in Treatment of Patients w/EGFR-overexpressing 'Triple Receptor-negative' Metastatic Carcinoma of Breast That Progressed on Anthracyclines and Taxanes Terminated NCT00739063 Phase 2 Tarceva
8 A Phase Ib Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC) Recruiting NCT03855358 Phase 1 TQB2450 Injection and Anlotinib Hydrochioride Capsules

Search NIH Clinical Center for Triple-Receptor Negative Breast Cancer

Genetic Tests for Triple-Receptor Negative Breast Cancer

Anatomical Context for Triple-Receptor Negative Breast Cancer

MalaCards organs/tissues related to Triple-Receptor Negative Breast Cancer:

40
Breast, Lymph Node, Brain, Lung, Thyroid

Publications for Triple-Receptor Negative Breast Cancer

Articles related to Triple-Receptor Negative Breast Cancer:

(show all 24)
# Title Authors PMID Year
1
Development of Therapeutic Anti-JAGGED1 Antibodies for Cancer Therapy. 61
31395687 2019
2
Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. 61
29235566 2018
3
The depalmitoylase APT1 directs the asymmetric partitioning of Notch and Wnt signaling during cell division. 61
29295957 2018
4
A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers. 61
27126996 2016
5
Death-associated protein kinase 1 promotes growth of p53-mutant cancers. 61
26075823 2015
6
Updates from the 2014 San antonio breast cancer symposium. 61
25810580 2015
7
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. 61
24669015 2014
8
Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy. 61
23925999 2013
9
Mesothelin expression and survival outcomes in triple receptor negative breast cancer. 61
23810431 2013
10
Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. 61
22359359 2012
11
Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. 61
23040004 2012
12
Triple receptor-negative breast cancer: imaging and clinical characteristics. 61
22826413 2012
13
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. 61
21800293 2012
14
Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. 61
21331622 2012
15
A case of brain metastases from breast cancer treated with whole-brain radiotherapy and eribulin mesylate. 61
22953094 2012
16
Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. 61
21606433 2011
17
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. 61
21233401 2011
18
Triple-negative breast cancer: epidemiology and management options. 61
21080741 2010
19
Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer? 61
20580045 2010
20
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. 61
19596702 2009
21
Survival among women with triple receptor-negative breast cancer and brain metastases. 61
19150943 2009
22
Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. 61
19156929 2009
23
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. 61
19047281 2009
24
Advances in triple receptor-negative breast cancer. 61
18277956 2007

Variations for Triple-Receptor Negative Breast Cancer

Expression for Triple-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Triple-Receptor Negative Breast Cancer.

Pathways for Triple-Receptor Negative Breast Cancer

Pathways related to Triple-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.72 LYPLA1 LPAR3 LPAR2
2 10.1 LPAR3 LPAR2
3 9.7 LINC-ROR HOTAIR

GO Terms for Triple-Receptor Negative Breast Cancer

Molecular functions related to Triple-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lysophosphatidic acid receptor activity GO:0070915 8.62 LPAR3 LPAR2

Sources for Triple-Receptor Negative Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....